| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DiGeorge Syndrome | 43 | 2026 | 49 | 14.680 |
Why?
|
| Immunologic Deficiency Syndromes | 57 | 2025 | 65 | 13.660 |
Why?
|
| Common Variable Immunodeficiency | 27 | 2025 | 31 | 6.830 |
Why?
|
| Lupus Erythematosus, Systemic | 19 | 2024 | 203 | 6.730 |
Why?
|
| B-Lymphocytes | 24 | 2026 | 189 | 5.650 |
Why?
|
| T-Lymphocytes | 31 | 2025 | 386 | 5.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 32 | 2026 | 54 | 5.180 |
Why?
|
| Child | 126 | 2026 | 3443 | 4.780 |
Why?
|
| Child, Preschool | 94 | 2026 | 1546 | 4.610 |
Why?
|
| Humans | 349 | 2026 | 43102 | 4.600 |
Why?
|
| Inflammatory Bowel Diseases | 19 | 2026 | 104 | 4.550 |
Why?
|
| Chromosomes, Human, Pair 22 | 21 | 2023 | 42 | 4.170 |
Why?
|
| Monocytes | 17 | 2024 | 277 | 4.100 |
Why?
|
| Rubella | 10 | 2025 | 16 | 3.930 |
Why?
|
| Rubella virus | 11 | 2024 | 12 | 3.660 |
Why?
|
| Chromosome Deletion | 24 | 2024 | 53 | 3.550 |
Why?
|
| Agammaglobulinemia | 17 | 2025 | 19 | 3.370 |
Why?
|
| Chromatin | 10 | 2024 | 186 | 3.250 |
Why?
|
| Autoimmune Diseases | 20 | 2025 | 65 | 3.140 |
Why?
|
| Infant | 65 | 2026 | 1175 | 3.120 |
Why?
|
| Adolescent | 106 | 2026 | 6081 | 3.110 |
Why?
|
| Genetic Diseases, X-Linked | 13 | 2025 | 16 | 3.090 |
Why?
|
| Influenza, Human | 12 | 2013 | 92 | 3.070 |
Why?
|
| Granuloma | 9 | 2022 | 24 | 2.980 |
Why?
|
| Severe Combined Immunodeficiency | 13 | 2023 | 14 | 2.970 |
Why?
|
| Female | 168 | 2026 | 24698 | 2.960 |
Why?
|
| Male | 168 | 2026 | 23409 | 2.790 |
Why?
|
| Influenza Vaccines | 11 | 2013 | 58 | 2.740 |
Why?
|
| Lymphopenia | 7 | 2022 | 17 | 2.690 |
Why?
|
| Phenotype | 32 | 2025 | 780 | 2.620 |
Why?
|
| Inflammation | 17 | 2022 | 758 | 2.590 |
Why?
|
| Genetic Testing | 9 | 2025 | 91 | 2.480 |
Why?
|
| Autoantibodies | 8 | 2025 | 117 | 2.460 |
Why?
|
| Allergy and Immunology | 5 | 2025 | 14 | 2.320 |
Why?
|
| Histones | 11 | 2024 | 197 | 2.310 |
Why?
|
| Autoimmunity | 16 | 2022 | 58 | 2.230 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 7 | 2024 | 13 | 2.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2021 | 384 | 2.070 |
Why?
|
| Granulomatous Disease, Chronic | 11 | 2022 | 11 | 2.070 |
Why?
|
| Adult | 107 | 2026 | 13872 | 2.070 |
Why?
|
| Young Adult | 57 | 2026 | 5080 | 2.010 |
Why?
|
| Interferon Regulatory Factor-1 | 5 | 2019 | 6 | 1.980 |
Why?
|
| Lupus Nephritis | 6 | 2024 | 26 | 1.960 |
Why?
|
| Genetic Predisposition to Disease | 19 | 2025 | 734 | 1.940 |
Why?
|
| RNA-Binding Proteins | 7 | 2020 | 161 | 1.850 |
Why?
|
| Registries | 26 | 2023 | 437 | 1.780 |
Why?
|
| Hypersensitivity | 7 | 2025 | 32 | 1.770 |
Why?
|
| Gene Expression Regulation | 13 | 2021 | 1070 | 1.750 |
Why?
|
| Lipopolysaccharides | 7 | 2020 | 239 | 1.690 |
Why?
|
| Lymphoproliferative Disorders | 7 | 2024 | 12 | 1.670 |
Why?
|
| Thymus Gland | 5 | 2022 | 76 | 1.610 |
Why?
|
| Epigenesis, Genetic | 5 | 2024 | 291 | 1.580 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2021 | 279 | 1.540 |
Why?
|
| Diagnosis, Differential | 22 | 2024 | 238 | 1.530 |
Why?
|
| Mutation | 28 | 2025 | 1177 | 1.520 |
Why?
|
| Infant, Newborn | 36 | 2023 | 972 | 1.500 |
Why?
|
| Cytokines | 13 | 2025 | 678 | 1.480 |
Why?
|
| Complement System Proteins | 4 | 2022 | 25 | 1.470 |
Why?
|
| Macrophages | 8 | 2021 | 529 | 1.450 |
Why?
|
| E1A-Associated p300 Protein | 3 | 2024 | 11 | 1.440 |
Why?
|
| Immune System Diseases | 8 | 2022 | 21 | 1.400 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2026 | 47 | 1.400 |
Why?
|
| Immunity | 7 | 2024 | 61 | 1.370 |
Why?
|
| Diet | 9 | 2023 | 826 | 1.360 |
Why?
|
| Promoter Regions, Genetic | 13 | 2018 | 526 | 1.310 |
Why?
|
| Middle Aged | 60 | 2025 | 12222 | 1.260 |
Why?
|
| Killer Cells, Natural | 5 | 2025 | 104 | 1.260 |
Why?
|
| Signal Transduction | 18 | 2024 | 2157 | 1.210 |
Why?
|
| Animals, Zoo | 9 | 2023 | 14 | 1.210 |
Why?
|
| Transcription, Genetic | 4 | 2021 | 592 | 1.200 |
Why?
|
| Heart Defects, Congenital | 8 | 2024 | 72 | 1.190 |
Why?
|
| Neutropenia | 5 | 2022 | 11 | 1.170 |
Why?
|
| Retrospective Studies | 33 | 2025 | 2544 | 1.170 |
Why?
|
| Viral Vaccines | 4 | 2020 | 37 | 1.170 |
Why?
|
| Neonatal Screening | 8 | 2023 | 25 | 1.170 |
Why?
|
| Self Disclosure | 4 | 2010 | 44 | 1.160 |
Why?
|
| Age of Onset | 12 | 2022 | 114 | 1.160 |
Why?
|
| Genetic Association Studies | 6 | 2025 | 118 | 1.160 |
Why?
|
| Genetic Variation | 4 | 2021 | 430 | 1.140 |
Why?
|
| Sequence Deletion | 2 | 2019 | 93 | 1.120 |
Why?
|
| Thrombocytopenia | 4 | 2025 | 23 | 1.110 |
Why?
|
| Disease Susceptibility | 7 | 2021 | 101 | 1.080 |
Why?
|
| Osteomyelitis | 3 | 2013 | 20 | 1.060 |
Why?
|
| Sexual Partners | 5 | 2016 | 326 | 1.040 |
Why?
|
| Animal Husbandry | 6 | 2022 | 21 | 1.040 |
Why?
|
| Antibodies, Viral | 11 | 2025 | 306 | 1.010 |
Why?
|
| Lymphocyte Count | 12 | 2022 | 46 | 1.010 |
Why?
|
| Psychotic Disorders | 2 | 2025 | 71 | 1.000 |
Why?
|
| Cells, Cultured | 17 | 2021 | 1621 | 0.990 |
Why?
|
| Neutrophils | 5 | 2021 | 145 | 0.990 |
Why?
|
| Crohn Disease | 3 | 2014 | 71 | 0.960 |
Why?
|
| Histone Code | 3 | 2024 | 13 | 0.960 |
Why?
|
| Rheumatic Diseases | 2 | 2018 | 12 | 0.940 |
Why?
|
| Founder Effect | 1 | 2025 | 10 | 0.930 |
Why?
|
| RNA | 3 | 2022 | 266 | 0.930 |
Why?
|
| Anemia | 2 | 2022 | 55 | 0.920 |
Why?
|
| HIV Infections | 14 | 2016 | 2586 | 0.920 |
Why?
|
| Sepsis | 3 | 2024 | 90 | 0.920 |
Why?
|
| Immunoglobulins | 5 | 2022 | 39 | 0.910 |
Why?
|
| Lung Diseases | 2 | 2022 | 63 | 0.900 |
Why?
|
| Endotoxins | 2 | 2015 | 18 | 0.890 |
Why?
|
| Animals | 50 | 2024 | 16992 | 0.880 |
Why?
|
| Autoimmune Lymphoproliferative Syndrome | 1 | 2024 | 1 | 0.860 |
Why?
|
| Wiskott-Aldrich Syndrome | 4 | 2026 | 6 | 0.850 |
Why?
|
| Immunoglobulins, Intravenous | 5 | 2024 | 17 | 0.850 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2021 | 9 | 0.850 |
Why?
|
| HIV Seropositivity | 5 | 2014 | 196 | 0.840 |
Why?
|
| Vaccination | 7 | 2025 | 355 | 0.840 |
Why?
|
| Measles | 1 | 2023 | 7 | 0.830 |
Why?
|
| Thiazoles | 3 | 2019 | 76 | 0.830 |
Why?
|
| Neoplasms | 7 | 2022 | 1377 | 0.830 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 11 | 0.830 |
Why?
|
| I-kappa B Kinase | 1 | 2024 | 51 | 0.820 |
Why?
|
| Electronic Health Records | 1 | 2025 | 108 | 0.820 |
Why?
|
| Bronchiectasis | 3 | 2023 | 13 | 0.810 |
Why?
|
| Graft vs Host Disease | 10 | 2023 | 15 | 0.810 |
Why?
|
| Arthritis | 3 | 2017 | 18 | 0.810 |
Why?
|
| Cell Line | 13 | 2021 | 1410 | 0.810 |
Why?
|
| Toll-Like Receptors | 7 | 2019 | 51 | 0.810 |
Why?
|
| Micronutrients | 1 | 2023 | 45 | 0.800 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2013 | 38 | 0.790 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2020 | 91 | 0.790 |
Why?
|
| Protein Binding | 9 | 2019 | 1082 | 0.780 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2024 | 15 | 0.770 |
Why?
|
| Abnormalities, Multiple | 5 | 2023 | 38 | 0.770 |
Why?
|
| Prevalence | 20 | 2025 | 1612 | 0.770 |
Why?
|
| Bone Marrow Diseases | 1 | 2022 | 4 | 0.770 |
Why?
|
| Leukopenia | 1 | 2022 | 10 | 0.760 |
Why?
|
| Immunoglobulin G | 9 | 2020 | 259 | 0.760 |
Why?
|
| Complement Activation | 1 | 2022 | 14 | 0.760 |
Why?
|
| Horse Diseases | 1 | 2022 | 11 | 0.760 |
Why?
|
| Lymphocytes | 6 | 2022 | 124 | 0.760 |
Why?
|
| Iron Overload | 1 | 2022 | 10 | 0.760 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 140 | 0.750 |
Why?
|
| MicroRNAs | 3 | 2021 | 518 | 0.740 |
Why?
|
| Aged | 28 | 2025 | 8214 | 0.740 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 95 | 0.730 |
Why?
|
| Respiratory Tract Infections | 5 | 2022 | 36 | 0.730 |
Why?
|
| Immune Tolerance | 3 | 2017 | 68 | 0.710 |
Why?
|
| Keratinocytes | 3 | 2021 | 67 | 0.710 |
Why?
|
| Chemokine CXCL9 | 2 | 2021 | 3 | 0.690 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2021 | 1 | 0.690 |
Why?
|
| Deafness | 1 | 2021 | 7 | 0.680 |
Why?
|
| Interferon-alpha | 2 | 2024 | 43 | 0.670 |
Why?
|
| Chromatin Immunoprecipitation | 6 | 2018 | 74 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 497 | 0.670 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2021 | 64 | 0.660 |
Why?
|
| Complement C3 Nephritic Factor | 2 | 2017 | 2 | 0.650 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2022 | 32 | 0.650 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 75 | 0.650 |
Why?
|
| Influenza A virus | 2 | 2010 | 31 | 0.640 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 15 | 0.640 |
Why?
|
| Cell Differentiation | 7 | 2026 | 638 | 0.630 |
Why?
|
| Women | 2 | 2010 | 28 | 0.630 |
Why?
|
| Interleukin-1alpha | 1 | 2020 | 18 | 0.630 |
Why?
|
| DNA-Binding Proteins | 5 | 2015 | 561 | 0.630 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 38 | 0.630 |
Why?
|
| Arachnodactyly | 1 | 2019 | 2 | 0.620 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 94 | 0.610 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2019 | 28 | 0.610 |
Why?
|
| Transcription Initiation Site | 2 | 2016 | 14 | 0.600 |
Why?
|
| Colitis | 3 | 2021 | 71 | 0.600 |
Why?
|
| Interferons | 6 | 2024 | 40 | 0.600 |
Why?
|
| Prolactin | 1 | 2019 | 65 | 0.600 |
Why?
|
| Histone Acetyltransferases | 2 | 2019 | 21 | 0.600 |
Why?
|
| Germ-Line Mutation | 3 | 2025 | 75 | 0.600 |
Why?
|
| Immunity, Humoral | 2 | 2025 | 29 | 0.600 |
Why?
|
| Virus Diseases | 5 | 2021 | 27 | 0.590 |
Why?
|
| Animal Nutritional Physiological Phenomena | 5 | 2014 | 18 | 0.590 |
Why?
|
| ADAM Proteins | 1 | 2018 | 20 | 0.580 |
Why?
|
| Cohort Studies | 15 | 2024 | 1759 | 0.580 |
Why?
|
| NF-kappa B | 4 | 2018 | 358 | 0.570 |
Why?
|
| Genotype | 9 | 2025 | 800 | 0.570 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 432 | 0.560 |
Why?
|
| Antirheumatic Agents | 2 | 2022 | 37 | 0.560 |
Why?
|
| Recurrence | 6 | 2026 | 152 | 0.560 |
Why?
|
| Treatment Outcome | 15 | 2026 | 1604 | 0.560 |
Why?
|
| Abdominal Pain | 2 | 2016 | 24 | 0.560 |
Why?
|
| RNA, Messenger | 5 | 2024 | 1271 | 0.560 |
Why?
|
| Perissodactyla | 4 | 2022 | 4 | 0.560 |
Why?
|
| Tissue Banks | 1 | 2018 | 9 | 0.550 |
Why?
|
| Diagnosis | 1 | 2018 | 10 | 0.550 |
Why?
|
| Chronic Disease | 7 | 2023 | 549 | 0.550 |
Why?
|
| Thinness | 1 | 2018 | 32 | 0.550 |
Why?
|
| X-Linked Combined Immunodeficiency Diseases | 3 | 2019 | 3 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2018 | 26 | 0.550 |
Why?
|
| Opportunistic Infections | 4 | 2014 | 10 | 0.550 |
Why?
|
| Men | 2 | 2009 | 19 | 0.550 |
Why?
|
| Immunosuppressive Agents | 6 | 2018 | 94 | 0.540 |
Why?
|
| Prospective Studies | 10 | 2023 | 1600 | 0.540 |
Why?
|
| Immunophenotyping | 8 | 2024 | 57 | 0.540 |
Why?
|
| Immunologic Memory | 4 | 2015 | 42 | 0.530 |
Why?
|
| Ranidae | 2 | 2014 | 12 | 0.530 |
Why?
|
| Travel | 1 | 2017 | 36 | 0.530 |
Why?
|
| Complement Pathway, Alternative | 1 | 2017 | 2 | 0.530 |
Why?
|
| Organ Transplantation | 2 | 2021 | 24 | 0.530 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2017 | 15 | 0.520 |
Why?
|
| Case-Control Studies | 13 | 2024 | 1285 | 0.520 |
Why?
|
| Serpins | 1 | 2017 | 27 | 0.520 |
Why?
|
| Genome-Wide Association Study | 8 | 2024 | 423 | 0.520 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 49 | 0.520 |
Why?
|
| Acetylation | 6 | 2019 | 107 | 0.520 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 77 | 0.520 |
Why?
|
| Research Design | 2 | 2018 | 385 | 0.510 |
Why?
|
| Antineoplastic Agents | 4 | 2013 | 1019 | 0.510 |
Why?
|
| Splenic Diseases | 1 | 2016 | 3 | 0.510 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 20 | 0.510 |
Why?
|
| Vomiting | 1 | 2016 | 14 | 0.510 |
Why?
|
| Vitamin A | 2 | 2014 | 86 | 0.510 |
Why?
|
| Elephants | 1 | 2016 | 1 | 0.500 |
Why?
|
| Transcription Factors | 3 | 2017 | 735 | 0.500 |
Why?
|
| Epidermis | 1 | 2016 | 23 | 0.500 |
Why?
|
| United States | 28 | 2024 | 5205 | 0.500 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 90 | 0.490 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2015 | 64 | 0.490 |
Why?
|
| Microarray Analysis | 2 | 2018 | 64 | 0.490 |
Why?
|
| Enterovirus Infections | 1 | 2016 | 4 | 0.490 |
Why?
|
| Down-Regulation | 1 | 2018 | 456 | 0.480 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2015 | 8 | 0.480 |
Why?
|
| Syndrome | 8 | 2023 | 73 | 0.470 |
Why?
|
| Unsafe Sex | 2 | 2016 | 162 | 0.470 |
Why?
|
| Kidney | 3 | 2024 | 372 | 0.470 |
Why?
|
| Mesangial Cells | 1 | 2015 | 9 | 0.470 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 57 | 0.470 |
Why?
|
| Adoptive Transfer | 2 | 2012 | 53 | 0.470 |
Why?
|
| Lymphocyte Activation | 2 | 2015 | 249 | 0.460 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2015 | 19 | 0.460 |
Why?
|
| Animal Feed | 4 | 2012 | 53 | 0.450 |
Why?
|
| Repressor Proteins | 4 | 2021 | 273 | 0.450 |
Why?
|
| Brain | 3 | 2018 | 1472 | 0.450 |
Why?
|
| Bufonidae | 1 | 2014 | 1 | 0.450 |
Why?
|
| Body Weight | 2 | 2016 | 429 | 0.450 |
Why?
|
| CD40 Ligand | 3 | 2021 | 9 | 0.440 |
Why?
|
| Genetic Markers | 1 | 2015 | 150 | 0.440 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2021 | 12 | 0.440 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 704 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2016 | 41 | 0.440 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2005 | 58 | 0.440 |
Why?
|
| Pedigree | 6 | 2025 | 94 | 0.440 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2023 | 13 | 0.440 |
Why?
|
| Community Mental Health Services | 1 | 2014 | 34 | 0.430 |
Why?
|
| Mice | 19 | 2024 | 6644 | 0.430 |
Why?
|
| Potassium Channel Blockers | 3 | 2021 | 35 | 0.430 |
Why?
|
| Vaccines, Attenuated | 3 | 2020 | 75 | 0.430 |
Why?
|
| Creatinine | 4 | 2023 | 102 | 0.430 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 95 | 0.430 |
Why?
|
| Homosexuality | 1 | 2014 | 36 | 0.430 |
Why?
|
| RNA Polymerase II | 3 | 2017 | 31 | 0.430 |
Why?
|
| RNA, Small Nuclear | 1 | 2014 | 10 | 0.430 |
Why?
|
| Transplantation Conditioning | 7 | 2026 | 9 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 220 | 0.420 |
Why?
|
| Social Work | 1 | 2014 | 53 | 0.420 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 35 | 0.420 |
Why?
|
| Interferon-gamma | 2 | 2021 | 269 | 0.420 |
Why?
|
| Staff Development | 1 | 2014 | 30 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 14 | 0.420 |
Why?
|
| Flow Cytometry | 6 | 2015 | 411 | 0.420 |
Why?
|
| Sirolimus | 4 | 2009 | 70 | 0.420 |
Why?
|
| Cross-Sectional Studies | 15 | 2024 | 3156 | 0.410 |
Why?
|
| Frameshift Mutation | 3 | 2025 | 9 | 0.410 |
Why?
|
| Physicians | 2 | 2014 | 188 | 0.410 |
Why?
|
| Cell Proliferation | 6 | 2026 | 1455 | 0.410 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2020 | 652 | 0.410 |
Why?
|
| Drug Therapy | 1 | 2013 | 17 | 0.410 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2010 | 16 | 0.410 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 934 | 0.400 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 174 | 0.400 |
Why?
|
| Antigens, CD | 3 | 2014 | 127 | 0.400 |
Why?
|
| Mental Disorders | 1 | 2018 | 392 | 0.390 |
Why?
|
| Chromosomes | 3 | 2023 | 43 | 0.390 |
Why?
|
| Urticaria | 2 | 2018 | 5 | 0.390 |
Why?
|
| Mycoses | 3 | 2013 | 31 | 0.390 |
Why?
|
| Dermatomyositis | 2 | 2002 | 9 | 0.390 |
Why?
|
| Homozygote | 4 | 2025 | 77 | 0.380 |
Why?
|
| Anxiety | 2 | 2020 | 874 | 0.380 |
Why?
|
| Risk Factors | 14 | 2022 | 3994 | 0.370 |
Why?
|
| Hemagglutination Inhibition Tests | 4 | 2013 | 8 | 0.370 |
Why?
|
| Poly I-C | 2 | 2010 | 7 | 0.370 |
Why?
|
| Bone and Bones | 1 | 2013 | 114 | 0.370 |
Why?
|
| Pneumonia | 2 | 2023 | 61 | 0.370 |
Why?
|
| Intestinal Mucosa | 3 | 2026 | 134 | 0.370 |
Why?
|
| Gene Expression | 7 | 2021 | 701 | 0.370 |
Why?
|
| Trans-Activators | 2 | 2025 | 192 | 0.370 |
Why?
|
| Apoptosis | 7 | 2016 | 1568 | 0.370 |
Why?
|
| Dermatitis | 2 | 2022 | 10 | 0.360 |
Why?
|
| Excipients | 1 | 2012 | 25 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2011 | 4 | 0.360 |
Why?
|
| Proline | 1 | 2012 | 40 | 0.360 |
Why?
|
| Protein Transport | 3 | 2021 | 296 | 0.360 |
Why?
|
| Gene Deletion | 2 | 2015 | 168 | 0.360 |
Why?
|
| Neuroblastoma | 1 | 2012 | 136 | 0.350 |
Why?
|
| Liver | 2 | 2014 | 511 | 0.350 |
Why?
|
| Skin | 7 | 2023 | 187 | 0.350 |
Why?
|
| Polyendocrinopathies, Autoimmune | 2 | 2008 | 4 | 0.350 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 7 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2025 | 257 | 0.350 |
Why?
|
| Transplantation, Homologous | 7 | 2026 | 38 | 0.350 |
Why?
|
| Bone Morphogenetic Protein 4 | 2 | 2021 | 9 | 0.340 |
Why?
|
| Quality of Life | 3 | 2023 | 616 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2015 | 863 | 0.340 |
Why?
|
| Autoantigens | 2 | 2015 | 87 | 0.340 |
Why?
|
| Kidney Diseases | 3 | 2024 | 172 | 0.340 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2014 | 22 | 0.330 |
Why?
|
| Severity of Illness Index | 10 | 2022 | 719 | 0.330 |
Why?
|
| Genome, Human | 1 | 2011 | 144 | 0.330 |
Why?
|
| Urolithiasis | 1 | 2010 | 2 | 0.330 |
Why?
|
| Ruminants | 1 | 2010 | 7 | 0.330 |
Why?
|
| Dietary Supplements | 4 | 2023 | 213 | 0.330 |
Why?
|
| Sarcoma | 1 | 2010 | 11 | 0.330 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2010 | 14 | 0.330 |
Why?
|
| Iron | 3 | 2022 | 251 | 0.330 |
Why?
|
| Staphylococcus aureus | 2 | 2017 | 94 | 0.320 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 39 | 0.320 |
Why?
|
| Immune System | 1 | 2010 | 41 | 0.320 |
Why?
|
| Immunoglobulin M | 5 | 2024 | 86 | 0.320 |
Why?
|
| Lysosomes | 1 | 2010 | 86 | 0.320 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 48 | 0.320 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2010 | 19 | 0.320 |
Why?
|
| Duodenum | 2 | 2017 | 15 | 0.320 |
Why?
|
| Antigens, Viral | 2 | 2021 | 48 | 0.310 |
Why?
|
| Epithelial Cells | 2 | 2026 | 434 | 0.310 |
Why?
|
| DNA Repair | 3 | 2019 | 198 | 0.310 |
Why?
|
| Self Efficacy | 5 | 2014 | 215 | 0.310 |
Why?
|
| Sinusitis | 2 | 2023 | 20 | 0.300 |
Why?
|
| Immunization, Passive | 3 | 2024 | 19 | 0.300 |
Why?
|
| Bacterial Infections | 2 | 2014 | 45 | 0.300 |
Why?
|
| Up-Regulation | 6 | 2021 | 536 | 0.300 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 74 | 0.300 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 415 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 306 | 0.300 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 2853 | 0.290 |
Why?
|
| Diuretics | 3 | 2021 | 51 | 0.290 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1596 | 0.290 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2008 | 2 | 0.290 |
Why?
|
| North America | 5 | 2018 | 85 | 0.290 |
Why?
|
| Germinal Center | 2 | 2018 | 12 | 0.290 |
Why?
|
| Water Microbiology | 2 | 2021 | 81 | 0.280 |
Why?
|
| Base Sequence | 4 | 2014 | 983 | 0.280 |
Why?
|
| Conservation of Natural Resources | 3 | 2014 | 48 | 0.280 |
Why?
|
| STAT1 Transcription Factor | 2 | 2018 | 34 | 0.270 |
Why?
|
| Risk-Taking | 5 | 2014 | 457 | 0.270 |
Why?
|
| Eosinophilia | 3 | 2022 | 17 | 0.260 |
Why?
|
| Nervous System Malformations | 2 | 2024 | 3 | 0.260 |
Why?
|
| Autoimmune Diseases of the Nervous System | 2 | 2024 | 3 | 0.260 |
Why?
|
| Drug Hypersensitivity | 2 | 2017 | 6 | 0.260 |
Why?
|
| ras Proteins | 2 | 2024 | 54 | 0.260 |
Why?
|
| Diarrhea | 3 | 2021 | 95 | 0.260 |
Why?
|
| Condoms | 3 | 2016 | 150 | 0.260 |
Why?
|
| Acquired Hyperostosis Syndrome | 1 | 2007 | 2 | 0.260 |
Why?
|
| Prognosis | 5 | 2021 | 861 | 0.260 |
Why?
|
| Pain | 2 | 2007 | 290 | 0.260 |
Why?
|
| Splenomegaly | 3 | 2022 | 6 | 0.260 |
Why?
|
| Tibia | 1 | 2007 | 26 | 0.260 |
Why?
|
| Mannose-Binding Lectin | 2 | 2005 | 6 | 0.250 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2006 | 4 | 0.250 |
Why?
|
| Uveitis | 1 | 2006 | 5 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2024 | 69 | 0.250 |
Why?
|
| IgA Deficiency | 2 | 2019 | 6 | 0.250 |
Why?
|
| Philadelphia | 5 | 2025 | 20 | 0.250 |
Why?
|
| Antiviral Agents | 3 | 2017 | 195 | 0.250 |
Why?
|
| Polyomavirus Infections | 2 | 2017 | 18 | 0.250 |
Why?
|
| Food Hypersensitivity | 2 | 2017 | 5 | 0.250 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2006 | 2 | 0.250 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2026 | 1 | 0.250 |
Why?
|
| Immunoglobulin E | 4 | 2022 | 61 | 0.250 |
Why?
|
| Lupus Erythematosus, Cutaneous | 3 | 2016 | 5 | 0.240 |
Why?
|
| Health Care Costs | 2 | 2017 | 91 | 0.240 |
Why?
|
| Schnitzler Syndrome | 1 | 2005 | 1 | 0.240 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2024 | 58 | 0.240 |
Why?
|
| Sneddon Syndrome | 1 | 2005 | 1 | 0.240 |
Why?
|
| Antibodies, Neutralizing | 6 | 2025 | 127 | 0.240 |
Why?
|
| Skin Ulcer | 1 | 2025 | 6 | 0.240 |
Why?
|
| Bacterial Translocation | 1 | 2025 | 4 | 0.240 |
Why?
|
| Thrombosis | 1 | 2006 | 81 | 0.240 |
Why?
|
| Probiotics | 1 | 2006 | 37 | 0.240 |
Why?
|
| Lymphoma | 2 | 2020 | 41 | 0.230 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2005 | 2 | 0.230 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 19 | 0.230 |
Why?
|
| Complement Factor I | 1 | 2025 | 1 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2021 | 201 | 0.230 |
Why?
|
| Methylation | 2 | 2016 | 119 | 0.230 |
Why?
|
| Nepal | 1 | 2025 | 19 | 0.230 |
Why?
|
| Celiac Disease | 1 | 2005 | 4 | 0.230 |
Why?
|
| Mutation, Missense | 3 | 2025 | 91 | 0.230 |
Why?
|
| HMGB1 Protein | 1 | 2005 | 30 | 0.230 |
Why?
|
| Binding Sites | 3 | 2015 | 671 | 0.230 |
Why?
|
| Nutritional Status | 2 | 2023 | 119 | 0.230 |
Why?
|
| Hyperostosis, Cortical, Congenital | 1 | 2025 | 1 | 0.230 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2005 | 5 | 0.230 |
Why?
|
| Colon | 1 | 2026 | 120 | 0.230 |
Why?
|
| Artificial Intelligence | 2 | 2025 | 112 | 0.220 |
Why?
|
| Sexual Behavior | 2 | 2009 | 638 | 0.220 |
Why?
|
| Organoids | 2 | 2026 | 37 | 0.220 |
Why?
|
| Pregnancy | 2 | 2024 | 1772 | 0.220 |
Why?
|
| Hawaii | 7 | 2011 | 2011 | 0.220 |
Why?
|
| Extremities | 1 | 2004 | 20 | 0.220 |
Why?
|
| Osteoporosis | 1 | 2005 | 45 | 0.220 |
Why?
|
| Amphibians | 2 | 2014 | 9 | 0.220 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2024 | 3 | 0.220 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2004 | 10 | 0.220 |
Why?
|
| Haplotypes | 1 | 2025 | 197 | 0.220 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2024 | 4 | 0.220 |
Why?
|
| Edema | 1 | 2004 | 26 | 0.220 |
Why?
|
| Mass Screening | 1 | 2009 | 541 | 0.220 |
Why?
|
| Pilot Projects | 5 | 2014 | 760 | 0.220 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 333 | 0.220 |
Why?
|
| Down Syndrome | 1 | 2004 | 32 | 0.220 |
Why?
|
| Carrier Proteins | 2 | 2020 | 321 | 0.220 |
Why?
|
| Hereditary Autoinflammatory Diseases | 2 | 2021 | 2 | 0.220 |
Why?
|
| Computational Biology | 2 | 2019 | 327 | 0.220 |
Why?
|
| Sex Factors | 3 | 2020 | 1028 | 0.210 |
Why?
|
| Fatigue | 2 | 2020 | 100 | 0.210 |
Why?
|
| Empathy | 2 | 2015 | 33 | 0.210 |
Why?
|
| Chondrocytes | 2 | 2021 | 15 | 0.210 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 140 | 0.210 |
Why?
|
| Nitro Compounds | 3 | 2019 | 34 | 0.210 |
Why?
|
| Complement Membrane Attack Complex | 2 | 2020 | 3 | 0.210 |
Why?
|
| Proteomics | 2 | 2024 | 378 | 0.210 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 316 | 0.210 |
Why?
|
| Ultraviolet Rays | 4 | 2023 | 118 | 0.210 |
Why?
|
| Facies | 1 | 2023 | 4 | 0.210 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 2 | 2019 | 4 | 0.210 |
Why?
|
| Antibodies | 2 | 2020 | 144 | 0.210 |
Why?
|
| Asthma | 4 | 2020 | 416 | 0.210 |
Why?
|
| Hyperventilation | 1 | 2023 | 12 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2021 | 47 | 0.210 |
Why?
|
| Leukocyte Disorders | 1 | 2003 | 2 | 0.210 |
Why?
|
| Tissue Donors | 3 | 2021 | 53 | 0.210 |
Why?
|
| Chromosome Disorders | 1 | 2003 | 8 | 0.210 |
Why?
|
| Antigens, CD19 | 3 | 2015 | 16 | 0.210 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2023 | 10 | 0.210 |
Why?
|
| Immunotherapy | 2 | 2016 | 144 | 0.200 |
Why?
|
| Erythrocytes | 2 | 2024 | 126 | 0.200 |
Why?
|
| Polysaccharides | 1 | 2024 | 72 | 0.200 |
Why?
|
| Communication | 1 | 2005 | 210 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2024 | 81 | 0.200 |
Why?
|
| Adenosine Deaminase | 2 | 2020 | 21 | 0.200 |
Why?
|
| Cholecalciferol | 1 | 2023 | 20 | 0.200 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 278 | 0.200 |
Why?
|
| Lizards | 1 | 2023 | 27 | 0.200 |
Why?
|
| Time Factors | 8 | 2018 | 1857 | 0.200 |
Why?
|
| Rabbits | 1 | 2023 | 278 | 0.200 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 54 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 159 | 0.200 |
Why?
|
| Medication Adherence | 3 | 2014 | 182 | 0.190 |
Why?
|
| Abscess | 2 | 2017 | 10 | 0.190 |
Why?
|
| Xerostomia | 1 | 2022 | 3 | 0.190 |
Why?
|
| HLA-DR3 Antigen | 1 | 2002 | 1 | 0.190 |
Why?
|
| Iron Metabolism Disorders | 2 | 2012 | 3 | 0.190 |
Why?
|
| Aldehyde-Lyases | 1 | 2022 | 4 | 0.190 |
Why?
|
| Enteritis | 1 | 2022 | 6 | 0.190 |
Why?
|
| Complement C4 | 1 | 2022 | 4 | 0.190 |
Why?
|
| Complement Pathway, Classical | 1 | 2022 | 4 | 0.190 |
Why?
|
| Gastritis | 1 | 2022 | 13 | 0.190 |
Why?
|
| Th2 Cells | 2 | 2021 | 62 | 0.190 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2002 | 32 | 0.190 |
Why?
|
| Edetic Acid | 1 | 2022 | 23 | 0.190 |
Why?
|
| Horses | 1 | 2022 | 28 | 0.190 |
Why?
|
| Ethylenediamines | 1 | 2022 | 8 | 0.190 |
Why?
|
| Connective Tissue Diseases | 1 | 2022 | 5 | 0.190 |
Why?
|
| Transcriptional Activation | 2 | 2015 | 173 | 0.190 |
Why?
|
| Iron Chelating Agents | 1 | 2022 | 21 | 0.190 |
Why?
|
| Conjunctivitis | 1 | 2022 | 1 | 0.190 |
Why?
|
| Growth Disorders | 2 | 2021 | 23 | 0.190 |
Why?
|
| Proteinuria | 1 | 2022 | 56 | 0.190 |
Why?
|
| Genetic Counseling | 3 | 2023 | 15 | 0.190 |
Why?
|
| Vaccines, Inactivated | 2 | 2013 | 18 | 0.190 |
Why?
|
| Acetates | 1 | 2022 | 32 | 0.180 |
Why?
|
| Survivors | 2 | 2021 | 152 | 0.180 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2021 | 10 | 0.180 |
Why?
|
| Intestines | 1 | 2022 | 71 | 0.180 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 9 | 0.180 |
Why?
|
| Transplantation, Autologous | 2 | 2012 | 8 | 0.180 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 10 | 0.180 |
Why?
|
| Interferon Type I | 3 | 2024 | 18 | 0.180 |
Why?
|
| Adenoviruses, Human | 1 | 2021 | 4 | 0.180 |
Why?
|
| Internet | 2 | 2020 | 236 | 0.180 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2021 | 5 | 0.180 |
Why?
|
| Butterflies | 1 | 2021 | 3 | 0.180 |
Why?
|
| Natriuretic Agents | 1 | 2021 | 4 | 0.180 |
Why?
|
| TGF-beta Superfamily Proteins | 1 | 2021 | 1 | 0.180 |
Why?
|
| Kidney Glomerulus | 2 | 2017 | 86 | 0.180 |
Why?
|
| Chemokines | 2 | 2017 | 96 | 0.180 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 201 | 0.180 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 26 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 440 | 0.170 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 61 | 0.170 |
Why?
|
| Career Choice | 1 | 2021 | 52 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1067 | 0.170 |
Why?
|
| Heredity | 1 | 2020 | 7 | 0.170 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 2 | 0.170 |
Why?
|
| Osteogenesis | 1 | 2021 | 57 | 0.170 |
Why?
|
| Hyperostosis | 1 | 2020 | 1 | 0.170 |
Why?
|
| Critical Illness | 1 | 2021 | 47 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2013 | 247 | 0.170 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2020 | 12 | 0.170 |
Why?
|
| Biological Products | 1 | 2022 | 91 | 0.170 |
Why?
|
| Antigen Presentation | 1 | 2021 | 58 | 0.170 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2020 | 2 | 0.160 |
Why?
|
| Societies, Scientific | 2 | 2017 | 9 | 0.160 |
Why?
|
| Linear Models | 2 | 2012 | 317 | 0.160 |
Why?
|
| International Cooperation | 2 | 2017 | 52 | 0.160 |
Why?
|
| Proteome | 1 | 2021 | 152 | 0.160 |
Why?
|
| Telemedicine | 1 | 2024 | 234 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 92 | 0.160 |
Why?
|
| Bacteria | 2 | 2021 | 293 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 54 | 0.160 |
Why?
|
| Gastroenterology | 1 | 2020 | 8 | 0.160 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 1542 | 0.160 |
Why?
|
| Enzyme Inhibitors | 3 | 2016 | 458 | 0.160 |
Why?
|
| Dendritic Cells | 2 | 2021 | 132 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2003 | 380 | 0.160 |
Why?
|
| Heterozygote | 3 | 2025 | 110 | 0.160 |
Why?
|
| Fetus | 1 | 2020 | 101 | 0.160 |
Why?
|
| Organ Size | 1 | 2020 | 170 | 0.160 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 9 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2020 | 135 | 0.160 |
Why?
|
| Interleukin-4 | 2 | 2011 | 75 | 0.160 |
Why?
|
| Allergens | 2 | 2018 | 65 | 0.160 |
Why?
|
| Endotoxemia | 1 | 2019 | 5 | 0.160 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 263 | 0.160 |
Why?
|
| Mood Disorders | 1 | 2020 | 54 | 0.150 |
Why?
|
| Fibroblasts | 2 | 2022 | 281 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 184 | 0.150 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2019 | 11 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2014 | 883 | 0.150 |
Why?
|
| Drosophila melanogaster | 1 | 2021 | 193 | 0.150 |
Why?
|
| Homeodomain Proteins | 2 | 2022 | 150 | 0.150 |
Why?
|
| Tight Junctions | 1 | 2019 | 27 | 0.150 |
Why?
|
| Lung | 1 | 2022 | 492 | 0.150 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2019 | 7 | 0.150 |
Why?
|
| Logistic Models | 3 | 2015 | 1009 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 178 | 0.150 |
Why?
|
| Longevity | 1 | 2021 | 173 | 0.150 |
Why?
|
| Knowledge Bases | 1 | 2019 | 8 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2019 | 17 | 0.150 |
Why?
|
| Busulfan | 1 | 2018 | 4 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2019 | 30 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.150 |
Why?
|
| Congenital Abnormalities | 1 | 2019 | 21 | 0.150 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2018 | 11 | 0.140 |
Why?
|
| Poliovirus | 1 | 2018 | 5 | 0.140 |
Why?
|
| Guanylate Cyclase | 1 | 2018 | 21 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2014 | 486 | 0.140 |
Why?
|
| Pediatrics | 1 | 2019 | 70 | 0.140 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2022 | 34 | 0.140 |
Why?
|
| Incidence | 6 | 2020 | 1078 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2013 | 146 | 0.140 |
Why?
|
| Embryonic Development | 1 | 2019 | 83 | 0.140 |
Why?
|
| Eosinophils | 1 | 2018 | 24 | 0.140 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2018 | 3 | 0.140 |
Why?
|
| Piperazines | 2 | 2021 | 120 | 0.140 |
Why?
|
| Models, Theoretical | 2 | 2017 | 232 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 4 | 2015 | 515 | 0.140 |
Why?
|
| Escherichia coli | 1 | 2021 | 460 | 0.140 |
Why?
|
| Lymphedema | 1 | 2018 | 7 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2018 | 16 | 0.140 |
Why?
|
| Lectins, C-Type | 2 | 2015 | 37 | 0.140 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 41 | 0.140 |
Why?
|
| Rectal Fistula | 1 | 2017 | 1 | 0.140 |
Why?
|
| Mevalonate Kinase Deficiency | 1 | 2017 | 1 | 0.140 |
Why?
|
| Polyomavirus | 1 | 2017 | 3 | 0.140 |
Why?
|
| Mevalonic Acid | 1 | 2017 | 12 | 0.140 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2017 | 7 | 0.140 |
Why?
|
| Esophagus | 1 | 2018 | 42 | 0.140 |
Why?
|
| Rectum | 1 | 2017 | 27 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Anemia, Hemolytic | 1 | 2017 | 8 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 149 | 0.140 |
Why?
|
| World Health Organization | 1 | 2017 | 36 | 0.140 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 11 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 31 | 0.140 |
Why?
|
| Centromere | 1 | 2017 | 21 | 0.140 |
Why?
|
| Aspergillus fumigatus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Tooth | 1 | 2017 | 11 | 0.140 |
Why?
|
| Otitis Media | 1 | 2017 | 2 | 0.140 |
Why?
|
| Failure to Thrive | 1 | 2017 | 3 | 0.130 |
Why?
|
| Bronchitis | 1 | 2017 | 5 | 0.130 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2010 | 43 | 0.130 |
Why?
|
| Minority Groups | 1 | 2023 | 690 | 0.130 |
Why?
|
| Cell Survival | 3 | 2017 | 945 | 0.130 |
Why?
|
| Lipodystrophy, Familial Partial | 1 | 2017 | 1 | 0.130 |
Why?
|
| Dyskeratosis Congenita | 2 | 2014 | 2 | 0.130 |
Why?
|
| Phagocytosis | 1 | 2017 | 86 | 0.130 |
Why?
|
| K562 Cells | 2 | 2014 | 32 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 2 | 2008 | 78 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2017 | 37 | 0.130 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 39 | 0.130 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2016 | 2 | 0.130 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2017 | 11 | 0.130 |
Why?
|
| Penicillins | 1 | 2016 | 10 | 0.130 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 7 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 63 | 0.130 |
Why?
|
| Vasoconstriction | 1 | 2017 | 42 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 84 | 0.130 |
Why?
|
| Gene Frequency | 4 | 2017 | 206 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2016 | 28 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2016 | 31 | 0.130 |
Why?
|
| SEER Program | 1 | 2017 | 164 | 0.130 |
Why?
|
| Kidney Tubules | 1 | 2017 | 39 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2017 | 67 | 0.130 |
Why?
|
| Receptors, Interferon | 1 | 2016 | 14 | 0.130 |
Why?
|
| Oxazines | 1 | 2016 | 32 | 0.130 |
Why?
|
| Heterocyclic Compounds | 1 | 2016 | 23 | 0.120 |
Why?
|
| Reproduction | 2 | 2016 | 94 | 0.120 |
Why?
|
| Self Concept | 2 | 2015 | 171 | 0.120 |
Why?
|
| Hyper-IgM Immunodeficiency Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| alpha-Tocopherol | 1 | 2016 | 27 | 0.120 |
Why?
|
| Complement C3 | 1 | 2016 | 16 | 0.120 |
Why?
|
| Sulfones | 1 | 2016 | 47 | 0.120 |
Why?
|
| Phenyl Ethers | 1 | 2016 | 4 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 228 | 0.120 |
Why?
|
| Fetal Blood | 1 | 2016 | 48 | 0.120 |
Why?
|
| Fontan Procedure | 1 | 2016 | 11 | 0.120 |
Why?
|
| Enterovirus | 1 | 2016 | 11 | 0.120 |
Why?
|
| Siblings | 3 | 2019 | 22 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 587 | 0.120 |
Why?
|
| Salix | 1 | 2015 | 2 | 0.120 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 3 | 0.120 |
Why?
|
| Eczema | 2 | 2025 | 5 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 68 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2020 | 207 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 31 | 0.120 |
Why?
|
| Trichomonas vaginalis | 1 | 2015 | 9 | 0.120 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2015 | 16 | 0.120 |
Why?
|
| Genomics | 1 | 2018 | 293 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 22 | 0.120 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 95 | 0.120 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 25 | 0.120 |
Why?
|
| Food Analysis | 1 | 2015 | 34 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 223 | 0.120 |
Why?
|
| Nutritive Value | 1 | 2015 | 37 | 0.110 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2015 | 14 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 139 | 0.110 |
Why?
|
| BK Virus | 1 | 2015 | 4 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 27 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 79 | 0.110 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2015 | 5 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 8 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 245 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2015 | 22 | 0.110 |
Why?
|
| Virus Replication | 1 | 2017 | 318 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 196 | 0.110 |
Why?
|
| Virus Activation | 1 | 2015 | 38 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2021 | 1003 | 0.110 |
Why?
|
| Attitude to Health | 2 | 2009 | 338 | 0.110 |
Why?
|
| Drug Design | 1 | 2016 | 186 | 0.110 |
Why?
|
| Vitamin A Deficiency | 2 | 2014 | 13 | 0.110 |
Why?
|
| Chlamydia trachomatis | 1 | 2015 | 70 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 310 | 0.110 |
Why?
|
| Self Tolerance | 1 | 2014 | 6 | 0.110 |
Why?
|
| Life Cycle Stages | 1 | 2014 | 29 | 0.110 |
Why?
|
| Feces | 3 | 2021 | 132 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 355 | 0.110 |
Why?
|
| Pyrimidines | 3 | 2021 | 139 | 0.110 |
Why?
|
| Consensus | 2 | 2023 | 48 | 0.110 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2014 | 4 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Rats, Inbred SHR | 3 | 2021 | 30 | 0.110 |
Why?
|
| Florida | 1 | 2016 | 478 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 2 | 2024 | 196 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 1 | 0.110 |
Why?
|
| Liver Failure | 1 | 2014 | 6 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2009 | 226 | 0.110 |
Why?
|
| Lysine | 1 | 2015 | 119 | 0.110 |
Why?
|
| RNA Precursors | 1 | 2014 | 28 | 0.110 |
Why?
|
| Jacobsen Distal 11q Deletion Syndrome | 1 | 2014 | 1 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2016 | 48 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 2014 | 55 | 0.110 |
Why?
|
| Lasers | 1 | 2014 | 57 | 0.100 |
Why?
|
| Immunoglobulin A | 4 | 2020 | 65 | 0.100 |
Why?
|
| Age Factors | 3 | 2014 | 1154 | 0.100 |
Why?
|
| Viridans Streptococci | 1 | 2013 | 1 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2014 | 61 | 0.100 |
Why?
|
| Water | 1 | 2016 | 316 | 0.100 |
Why?
|
| Dogs | 3 | 2021 | 204 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 173 | 0.100 |
Why?
|
| Motor Neurons | 1 | 2014 | 90 | 0.100 |
Why?
|
| De Lange Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| Europe | 4 | 2020 | 115 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 158 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 210 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 29 | 0.100 |
Why?
|
| Streptococcal Infections | 1 | 2013 | 37 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 154 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 189 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2013 | 19 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2014 | 69 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2024 | 223 | 0.100 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 436 | 0.100 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 241 | 0.100 |
Why?
|
| Qc-SNARE Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Qb-SNARE Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Demography | 2 | 2012 | 195 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 14 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 247 | 0.100 |
Why?
|
| Skin Tests | 2 | 2016 | 13 | 0.100 |
Why?
|
| Protein-Losing Enteropathies | 2 | 2016 | 3 | 0.100 |
Why?
|
| Drug Combinations | 2 | 2021 | 104 | 0.100 |
Why?
|
| Bacterial Vaccines | 1 | 2014 | 129 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2020 | 74 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 18 | 0.100 |
Why?
|
| Environmental Monitoring | 2 | 2021 | 230 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 113 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 737 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2012 | 2 | 0.090 |
Why?
|
| Substance-Related Disorders | 3 | 2014 | 830 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 160 | 0.090 |
Why?
|
| Munc18 Proteins | 1 | 2012 | 2 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1063 | 0.090 |
Why?
|
| Actins | 1 | 2013 | 164 | 0.090 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2012 | 34 | 0.090 |
Why?
|
| Social Behavior | 1 | 2013 | 161 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 1124 | 0.090 |
Why?
|
| Pneumocystis carinii | 1 | 2011 | 2 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2015 | 403 | 0.090 |
Why?
|
| Alleles | 2 | 2025 | 352 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2012 | 23 | 0.090 |
Why?
|
| Databases, Genetic | 2 | 2025 | 103 | 0.090 |
Why?
|
| Bisexuality | 1 | 2014 | 211 | 0.090 |
Why?
|
| Depression | 2 | 2017 | 863 | 0.090 |
Why?
|
| Antigens, Bacterial | 1 | 2012 | 144 | 0.090 |
Why?
|
| Drug Stability | 1 | 2012 | 129 | 0.090 |
Why?
|
| Eurotiales | 1 | 2011 | 1 | 0.090 |
Why?
|
| Genetic Techniques | 1 | 2011 | 14 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 224 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2019 | 69 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 269 | 0.090 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2011 | 14 | 0.090 |
Why?
|
| DNA | 2 | 2005 | 592 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2009 | 575 | 0.080 |
Why?
|
| Nitriles | 2 | 2021 | 81 | 0.080 |
Why?
|
| RNA, Double-Stranded | 1 | 2010 | 24 | 0.080 |
Why?
|
| Washington | 1 | 2010 | 38 | 0.080 |
Why?
|
| Pyrazoles | 2 | 2021 | 103 | 0.080 |
Why?
|
| Homeostasis | 3 | 2014 | 192 | 0.080 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 24 | 0.080 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 25 | 0.080 |
Why?
|
| Urinalysis | 1 | 2010 | 34 | 0.080 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 64 | 0.080 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2010 | 1 | 0.080 |
Why?
|
| Endosomes | 1 | 2010 | 33 | 0.080 |
Why?
|
| Pseudomonas Infections | 1 | 2010 | 23 | 0.080 |
Why?
|
| Meningitis | 1 | 2010 | 10 | 0.080 |
Why?
|
| Disease Management | 2 | 2021 | 70 | 0.080 |
Why?
|
| Transgenes | 1 | 2010 | 65 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 200 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 94 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 161 | 0.080 |
Why?
|
| Nursing Assessment | 1 | 2009 | 6 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2010 | 18 | 0.080 |
Why?
|
| Nursing Methodology Research | 1 | 2009 | 15 | 0.080 |
Why?
|
| Psychological Theory | 1 | 2009 | 26 | 0.080 |
Why?
|
| Aging | 1 | 2015 | 783 | 0.080 |
Why?
|
| Leukemia | 1 | 2010 | 54 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 213 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2024 | 561 | 0.080 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 532 | 0.080 |
Why?
|
| Choanal Atresia | 1 | 2009 | 1 | 0.080 |
Why?
|
| Coloboma | 1 | 2009 | 1 | 0.080 |
Why?
|
| Facial Nerve Diseases | 1 | 2009 | 1 | 0.080 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2009 | 2 | 0.080 |
Why?
|
| Spleen | 3 | 2015 | 204 | 0.080 |
Why?
|
| Half-Life | 2 | 2021 | 63 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 18 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 1 | 0.080 |
Why?
|
| Educational Status | 2 | 2014 | 339 | 0.080 |
Why?
|
| Antibody Formation | 1 | 2009 | 76 | 0.070 |
Why?
|
| Self Care | 1 | 2011 | 175 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2009 | 140 | 0.070 |
Why?
|
| Community Health Services | 1 | 2011 | 206 | 0.070 |
Why?
|
| DNA Helicases | 1 | 2009 | 48 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2005 | 64 | 0.070 |
Why?
|
| Potassium | 2 | 2021 | 109 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2010 | 206 | 0.070 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2008 | 88 | 0.070 |
Why?
|
| Duodenitis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Proteins | 1 | 2011 | 382 | 0.070 |
Why?
|
| Vero Cells | 2 | 2019 | 112 | 0.070 |
Why?
|
| Biopsy | 2 | 2019 | 177 | 0.070 |
Why?
|
| Activating Transcription Factors | 1 | 2008 | 5 | 0.070 |
Why?
|
| Social Class | 1 | 2010 | 291 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2021 | 300 | 0.070 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2007 | 2 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 403 | 0.070 |
Why?
|
| DNA Primers | 1 | 2008 | 294 | 0.070 |
Why?
|
| Transcription Factor TFIID | 1 | 2007 | 2 | 0.070 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2007 | 2 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2008 | 57 | 0.070 |
Why?
|
| Phylogeny | 2 | 2022 | 769 | 0.070 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 23 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2025 | 74 | 0.070 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 3 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2010 | 986 | 0.070 |
Why?
|
| Synovial Fluid | 2 | 2018 | 6 | 0.070 |
Why?
|
| Forestry | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nicotine | 1 | 2010 | 302 | 0.070 |
Why?
|
| Rats | 4 | 2021 | 3735 | 0.070 |
Why?
|
| Pennsylvania | 2 | 2021 | 43 | 0.070 |
Why?
|
| Water Supply | 1 | 2007 | 60 | 0.060 |
Why?
|
| Photosensitivity Disorders | 1 | 2006 | 5 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2007 | 100 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2005 | 187 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 100 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2006 | 4 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1234 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 2676 | 0.060 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2006 | 8 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 139 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2007 | 183 | 0.060 |
Why?
|
| Low Back Pain | 1 | 1998 | 101 | 0.060 |
Why?
|
| Plasma Cells | 1 | 2026 | 12 | 0.060 |
Why?
|
| Skin Diseases, Vascular | 1 | 2005 | 4 | 0.060 |
Why?
|
| Raynaud Disease | 1 | 2005 | 8 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2005 | 8 | 0.060 |
Why?
|
| Sexual Abstinence | 1 | 2005 | 8 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 368 | 0.060 |
Why?
|
| Expert Testimony | 2 | 2015 | 4 | 0.060 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2026 | 47 | 0.060 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2005 | 1 | 0.060 |
Why?
|
| Liver Abscess | 1 | 2005 | 3 | 0.060 |
Why?
|
| Boston | 1 | 2005 | 32 | 0.060 |
Why?
|
| Nurse's Role | 1 | 2005 | 37 | 0.060 |
Why?
|
| Geologic Sediments | 2 | 2021 | 46 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 2019 | 91 | 0.060 |
Why?
|
| Rivers | 2 | 2021 | 51 | 0.060 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.060 |
Why?
|
| Penetrance | 1 | 2025 | 7 | 0.060 |
Why?
|
| Stereotyping | 1 | 2005 | 45 | 0.060 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2005 | 5 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2025 | 50 | 0.060 |
Why?
|
| Leukotrienes | 1 | 2005 | 4 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 20 | 0.060 |
Why?
|
| Safe Sex | 1 | 2005 | 78 | 0.060 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2005 | 3 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 235 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2025 | 8 | 0.060 |
Why?
|
| Craniofacial Abnormalities | 1 | 2005 | 24 | 0.060 |
Why?
|
| Models, Animal | 2 | 2017 | 151 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2005 | 27 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2005 | 29 | 0.060 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 13 | 0.060 |
Why?
|
| Interleukins | 1 | 2005 | 40 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 386 | 0.060 |
Why?
|
| Mupirocin | 1 | 2004 | 1 | 0.060 |
Why?
|
| Naproxen | 1 | 2004 | 9 | 0.060 |
Why?
|
| Arthralgia | 1 | 2004 | 12 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 22 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 12 | 0.060 |
Why?
|
| Orthomyxoviridae | 1 | 2004 | 5 | 0.060 |
Why?
|
| Mice, Inbred NZB | 1 | 2024 | 1 | 0.050 |
Why?
|
| Gender Identity | 1 | 2005 | 117 | 0.050 |
Why?
|
| Mast Cells | 1 | 2005 | 82 | 0.050 |
Why?
|
| HIV-1 | 1 | 2010 | 755 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2004 | 89 | 0.050 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2005 | 129 | 0.050 |
Why?
|
| Fever | 1 | 2004 | 62 | 0.050 |
Why?
|
| Stem Cells | 2 | 2021 | 152 | 0.050 |
Why?
|
| Quinazolines | 1 | 2024 | 38 | 0.050 |
Why?
|
| Periodontitis | 1 | 2005 | 62 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 175 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 2 | 2019 | 7 | 0.050 |
Why?
|
| Kinetics | 1 | 2005 | 695 | 0.050 |
Why?
|
| Chickenpox Vaccine | 1 | 2003 | 2 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 143 | 0.050 |
Why?
|
| Critical Care | 1 | 2024 | 49 | 0.050 |
Why?
|
| DNA Damage | 1 | 2006 | 356 | 0.050 |
Why?
|
| Chickenpox | 1 | 2003 | 6 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2005 | 222 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 694 | 0.050 |
Why?
|
| Animals, Poisonous | 1 | 2023 | 1 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2015 | 37 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 26 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2024 | 57 | 0.050 |
Why?
|
| Fibrosis | 1 | 2024 | 169 | 0.050 |
Why?
|
| Data Mining | 1 | 2023 | 30 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2023 | 23 | 0.050 |
Why?
|
| U937 Cells | 1 | 2003 | 31 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 116 | 0.050 |
Why?
|
| Safety | 1 | 2003 | 54 | 0.050 |
Why?
|
| Butyrates | 1 | 2003 | 34 | 0.050 |
Why?
|
| Telomere | 1 | 2003 | 59 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2002 | 1 | 0.050 |
Why?
|
| Hypocalcemia | 1 | 2002 | 4 | 0.050 |
Why?
|
| Facial Bones | 1 | 2002 | 6 | 0.050 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 41 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 21 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2003 | 46 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2022 | 21 | 0.050 |
Why?
|
| Calcium | 2 | 2017 | 491 | 0.050 |
Why?
|
| Chromium | 1 | 2022 | 28 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2022 | 40 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 10 | 0.050 |
Why?
|
| Steroids | 1 | 2022 | 45 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 299 | 0.050 |
Why?
|
| Social Support | 1 | 2005 | 445 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 65 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2017 | 341 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 152 | 0.050 |
Why?
|
| Group II Phospholipases A2 | 1 | 2021 | 3 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 97 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2002 | 168 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 518 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 102 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1766 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2021 | 33 | 0.040 |
Why?
|
| Saliva | 1 | 2022 | 119 | 0.040 |
Why?
|
| Stroke | 1 | 2005 | 340 | 0.040 |
Why?
|
| Lymphopoiesis | 1 | 2021 | 1 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2002 | 124 | 0.040 |
Why?
|
| Haplorhini | 1 | 2021 | 23 | 0.040 |
Why?
|
| Enzyme Assays | 1 | 2021 | 13 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2023 | 263 | 0.040 |
Why?
|
| Parents | 1 | 2005 | 370 | 0.040 |
Why?
|
| Motivation | 1 | 2005 | 513 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2021 | 49 | 0.040 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2021 | 4 | 0.040 |
Why?
|
| Vitamin D | 1 | 2023 | 196 | 0.040 |
Why?
|
| Interleukin-10 | 1 | 2021 | 87 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2021 | 27 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 53 | 0.040 |
Why?
|
| Alberta | 1 | 2021 | 2 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2021 | 9 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2021 | 25 | 0.040 |
Why?
|
| Benzofurans | 1 | 2021 | 22 | 0.040 |
Why?
|
| Genes, X-Linked | 1 | 2021 | 9 | 0.040 |
Why?
|
| British Columbia | 1 | 2021 | 20 | 0.040 |
Why?
|
| Ontario | 1 | 2021 | 39 | 0.040 |
Why?
|
| Managed Care Programs | 1 | 2021 | 40 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2020 | 7 | 0.040 |
Why?
|
| Larva | 1 | 2021 | 133 | 0.040 |
Why?
|
| Myeloablative Agonists | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 655 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 9 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 171 | 0.040 |
Why?
|
| Lymphocytosis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 82 | 0.040 |
Why?
|
| Pseudolymphoma | 1 | 2020 | 5 | 0.040 |
Why?
|
| Cause of Death | 2 | 2015 | 186 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 98 | 0.040 |
Why?
|
| Species Specificity | 1 | 2021 | 286 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 91 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 60 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 485 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2002 | 141 | 0.040 |
Why?
|
| Homosexuality, Male | 1 | 2005 | 486 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2012 | 199 | 0.040 |
Why?
|
| Virus Shedding | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 835 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 181 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2019 | 6 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 114 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 518 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 188 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Action Potentials | 1 | 2021 | 246 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2019 | 13 | 0.040 |
Why?
|
| Nijmegen Breakage Syndrome | 1 | 2019 | 1 | 0.040 |
Why?
|
| Hirschsprung Disease | 1 | 2019 | 2 | 0.040 |
Why?
|
| Osteochondrodysplasias | 1 | 2019 | 2 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 321 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2019 | 119 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2019 | 28 | 0.040 |
Why?
|
| Hair | 1 | 2019 | 38 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2019 | 91 | 0.040 |
Why?
|
| Viral Load | 2 | 2015 | 348 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 240 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1081 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 39 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 37 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2018 | 16 | 0.030 |
Why?
|
| Remission Induction | 1 | 2017 | 19 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 51 | 0.030 |
Why?
|
| Quebec | 1 | 2017 | 4 | 0.030 |
Why?
|
| Immunization | 1 | 2018 | 94 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2017 | 38 | 0.030 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2017 | 1 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 666 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2017 | 99 | 0.030 |
Why?
|
| Face | 1 | 2017 | 40 | 0.030 |
Why?
|
| Thiadiazoles | 1 | 2017 | 6 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2017 | 5 | 0.030 |
Why?
|
| Hydrostatic Pressure | 1 | 2017 | 9 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 9 | 0.030 |
Why?
|
| Natriuresis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Furosemide | 1 | 2017 | 12 | 0.030 |
Why?
|
| Renal Circulation | 1 | 2017 | 20 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2017 | 16 | 0.030 |
Why?
|
| Epilepsy | 1 | 2017 | 59 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2017 | 36 | 0.030 |
Why?
|
| Exanthema | 1 | 2016 | 12 | 0.030 |
Why?
|
| Diuresis | 1 | 2016 | 7 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 175 | 0.030 |
Why?
|
| Feedback | 1 | 2017 | 56 | 0.030 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2016 | 2 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 147 | 0.030 |
Why?
|
| Water Pollution | 1 | 2016 | 13 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 458 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 165 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 611 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 139 | 0.030 |
Why?
|
| Starfish | 1 | 1975 | 3 | 0.030 |
Why?
|
| Digestive System | 1 | 1975 | 21 | 0.030 |
Why?
|
| Carbohydrate Metabolism | 1 | 1975 | 26 | 0.030 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.030 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2015 | 1 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2015 | 76 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 114 | 0.030 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 25 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 26 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2019 | 876 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 506 | 0.030 |
Why?
|
| Cystitis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 107 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 60 | 0.030 |
Why?
|
| Hematuria | 1 | 2015 | 6 | 0.030 |
Why?
|
| Namibia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 75 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 51 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2015 | 88 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 667 | 0.030 |
Why?
|
| Ovary | 1 | 1975 | 113 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 74 | 0.030 |
Why?
|
| Viremia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 86 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 37 | 0.030 |
Why?
|
| Gryllidae | 1 | 2014 | 3 | 0.030 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Plant Leaves | 1 | 2015 | 136 | 0.030 |
Why?
|
| Fatty Acids | 1 | 1975 | 134 | 0.030 |
Why?
|
| Breeding | 1 | 2014 | 28 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 11 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 47 | 0.030 |
Why?
|
| Canada | 1 | 2015 | 163 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 104 | 0.030 |
Why?
|
| Mannose-Binding Lectins | 1 | 2014 | 14 | 0.030 |
Why?
|
| Testis | 1 | 1975 | 207 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 287 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2014 | 4 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 2014 | 34 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2014 | 53 | 0.030 |
Why?
|
| China | 1 | 2015 | 229 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2014 | 58 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 2013 | 6 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 68 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 53 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 56 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2014 | 51 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 172 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 146 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2013 | 7 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2013 | 11 | 0.030 |
Why?
|
| Crime | 1 | 2013 | 29 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 587 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2014 | 114 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 215 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2014 | 172 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2013 | 65 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 174 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2012 | 5 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 302 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2014 | 490 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2014 | 178 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2012 | 52 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2012 | 9 | 0.020 |
Why?
|
| Ferritins | 1 | 2012 | 63 | 0.020 |
Why?
|
| Plants | 1 | 2012 | 113 | 0.020 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2011 | 5 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2011 | 49 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2010 | 39 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 863 | 0.020 |
Why?
|
| Cultural Characteristics | 1 | 2011 | 128 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 523 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 260 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 71 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 61 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 153 | 0.020 |
Why?
|
| Education | 1 | 2008 | 60 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 93 | 0.020 |
Why?
|
| Work | 1 | 1998 | 7 | 0.020 |
Why?
|
| France | 1 | 1998 | 23 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2012 | 1413 | 0.020 |
Why?
|
| Social Adjustment | 1 | 1998 | 30 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 62 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 509 | 0.020 |
Why?
|
| Leisure Activities | 1 | 1998 | 41 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2007 | 6 | 0.020 |
Why?
|
| Analgesics | 1 | 1998 | 55 | 0.020 |
Why?
|
| Intestine, Large | 1 | 2007 | 5 | 0.020 |
Why?
|
| Uncertainty | 1 | 2007 | 32 | 0.020 |
Why?
|
| Endoscopy | 1 | 2007 | 17 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 110 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2007 | 34 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 139 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2006 | 10 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2006 | 37 | 0.020 |
Why?
|
| Chloroquine | 1 | 1976 | 19 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 14 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2006 | 42 | 0.020 |
Why?
|
| Lymphoid Tissue | 1 | 2006 | 19 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2006 | 17 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2006 | 83 | 0.020 |
Why?
|
| Plasmodium berghei | 1 | 1976 | 34 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2006 | 16 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1976 | 13 | 0.020 |
Why?
|
| Albumins | 1 | 1976 | 33 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 100 | 0.010 |
Why?
|
| Antimalarials | 1 | 1976 | 64 | 0.010 |
Why?
|
| Russia | 1 | 2005 | 29 | 0.010 |
Why?
|
| Sodium | 1 | 1976 | 102 | 0.010 |
Why?
|
| Ear | 1 | 2005 | 4 | 0.010 |
Why?
|
| Acidosis | 1 | 1976 | 51 | 0.010 |
Why?
|
| Karyotyping | 1 | 2005 | 45 | 0.010 |
Why?
|
| Infant, Premature, Diseases | 1 | 1976 | 65 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2011 | 502 | 0.010 |
Why?
|
| Hypophosphatasia | 1 | 2005 | 1 | 0.010 |
Why?
|
| Papillon-Lefevre Disease | 1 | 2005 | 1 | 0.010 |
Why?
|
| California | 1 | 2007 | 548 | 0.010 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2005 | 4 | 0.010 |
Why?
|
| Urban Health | 1 | 2005 | 101 | 0.010 |
Why?
|
| Eikenella corrodens | 1 | 1975 | 2 | 0.010 |
Why?
|
| Bacteroides | 1 | 1975 | 10 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 6 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 2004 | 7 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 102 | 0.010 |
Why?
|
| Needle Sharing | 1 | 2003 | 11 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2003 | 97 | 0.010 |
Why?
|
| Acetophenones | 1 | 2002 | 10 | 0.010 |
Why?
|
| Protein Kinase C-delta | 1 | 2002 | 17 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2002 | 30 | 0.010 |
Why?
|
| Benzopyrans | 1 | 2002 | 25 | 0.010 |
Why?
|
| Morpholines | 1 | 2002 | 72 | 0.010 |
Why?
|
| Chromones | 1 | 2002 | 53 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 148 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 227 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 47 | 0.010 |
Why?
|
| Periodicity | 1 | 1975 | 34 | 0.010 |
Why?
|
| Digitoxigenin | 1 | 1975 | 4 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1975 | 12 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 39 | 0.010 |
Why?
|
| NADP | 1 | 1975 | 37 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1975 | 141 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1976 | 9 | 0.000 |
Why?
|
| Vacuoles | 1 | 1976 | 22 | 0.000 |
Why?
|
| Quinine | 1 | 1976 | 12 | 0.000 |
Why?
|
| Phenanthrenes | 1 | 1976 | 16 | 0.000 |
Why?
|
| Pigments, Biological | 1 | 1976 | 19 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1976 | 13 | 0.000 |
Why?
|
| Piperidines | 1 | 1976 | 83 | 0.000 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 1976 | 20 | 0.000 |
Why?
|
| Quinolines | 1 | 1976 | 78 | 0.000 |
Why?
|
| Carbon Dioxide | 1 | 1976 | 86 | 0.000 |
Why?
|
| Malaria | 1 | 1976 | 90 | 0.000 |
Why?
|
| Injections, Intramuscular | 1 | 1975 | 21 | 0.000 |
Why?
|
| Leg | 1 | 1975 | 19 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 34 | 0.000 |
Why?
|
| Suspensions | 1 | 1975 | 48 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1976 | 104 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1976 | 388 | 0.000 |
Why?
|
| Heart | 1 | 1975 | 184 | 0.000 |
Why?
|